Nebivolol, an antihypertensive agent, has new application in inhibiting melanoma.
Anticancer Drugs
; 35(6): 512-524, 2024 Jul 01.
Article
em En
| MEDLINE
| ID: mdl-38602174
ABSTRACT
Repurposing existing drugs for cancer therapy has become an important strategy because of its advantages, such as cost reduction, effect and safety. The present study was designed to investigate the antimelanoma effect and possible mechanisms of action of nebivolol, which is an approved and widely prescribed antihypertensive agent. In this study, we explored the effect of nebivolol on cell proliferation and cell activity in melanoma in vitro and the potential antimelanoma mechanism of nebivolol through a series of experiments, including the analysis of the effects with regard to cell apoptosis and metastasis. Furthermore, we evaluated the antimelanoma effect on xenograft tumor models and inspected the antimelanoma mechanism of nebivolol in vivo using immunohistochemical and immunofluorescence staining assays. As results in this work, in vitro , nebivolol possessed a strong activity for suppression proliferation and cell cycle arrest on melanoma. Moreover, nebivolol significantly induced cell apoptosis in melanoma through a mitochondrial-mediated endogenous apoptosis pathway. Additionally, nebivolol inhibited melanoma cell metastasis. More importantly, nebivolol exhibited significantly effective melanoma xenograft models in vivo , which related to the mechanism of apoptosis induction, proliferation inhibition, metastasis blocking and angiogenesis arrest. Overall, the data of the present study recommend that nebivolol holds great potential in application as a novel agent for the treatment of melanoma.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Apoptose
/
Ensaios Antitumorais Modelo de Xenoenxerto
/
Proliferação de Células
/
Nebivolol
/
Melanoma
/
Anti-Hipertensivos
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article